<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05001945</url>
  </required_header>
  <id_info>
    <org_study_id>MLS-101-201</org_study_id>
    <nct_id>NCT05001945</nct_id>
  </id_info>
  <brief_title>Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension</brief_title>
  <acronym>Target-HTN</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Phase 2 Study to Evaluate the Safety, Efficacy, and Tolerability of MLS-101 in Subjects With Uncontrolled Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mineralys Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mineralys Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled, dose-ranging, Phase II study to evaluate the&#xD;
      safety, efficacy, and tolerability of MLS-101 in Subjects With Uncontrolled Hypertension&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study-Wide Change in Systolic Blood Pressure</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Overall changes in SBP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-Hour Ambulatory Systolic and Diastolic Blood Pressure</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Overall changes in ambulatory blood pressure outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Changes in Systolic and Diastolic Blood Pressure</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Week-to-week changes in SBP and DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study-Wide Change in Diastolic Blood Pressure</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Overall changes in DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects with ≤ 130/80 mm Hg by End of Study</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Cohort-wide changes in blood pressure outcomes</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hypertension, Renal</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet(s) by mouth once or twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLS-101 tablet(s) by mouth once or twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLS-101 tablet(s) by mouth once or twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLS-101 tablet(s) by mouth once or twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLS-101 tablet(s) by mouth once or twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLS-101 tablet(s) by mouth once or twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLS-101</intervention_name>
    <description>MLS-101 tablet(s) by mouth once or twice daily.</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_label>Dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet(s) by mouth once or twice daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and nonpregnant, nonlactating female subjects ≥ 18 years of age.&#xD;
&#xD;
          2. Written informed consent Health Insurance Portability and Accountability Act&#xD;
             authorization, and local patient privacy required documentation for this study have&#xD;
             been obtained&#xD;
&#xD;
          3. Automated office blood pressure (AOBP) with SBP ≥ 130 mm Hg&#xD;
&#xD;
          4. Background antihypertensive treatment of ≥ 2 drugs&#xD;
&#xD;
          5. PRA ≤ 0.6 ng/mL&#xD;
&#xD;
          6. Serum aldosterone ≥ 6 ng/dL&#xD;
&#xD;
          7. Serum cortisol ≥ 18 mcg/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Concomitant use of epithelial sodium channel inhibitors or mineralocorticoid receptor&#xD;
        antagonists&#xD;
&#xD;
        3. Subjects with hypokalemia&#xD;
&#xD;
        4. Subjects with hyperkalemia&#xD;
&#xD;
        5. Subjects with serum cortisol &lt; 3 mcg/dL&#xD;
&#xD;
        6. Subjects with serum sodium &lt; 135 mEq/L&#xD;
&#xD;
        7. Subjects with estimated glomerular filtration rate &lt; 60 mL/min/1.73m2&#xD;
&#xD;
        8. Subjects with type 1 or uncontrolled (hemoglobin A1c ≥ 9%) type 2 diabetes mellitus&#xD;
&#xD;
        9. Subjects with body mass index &gt; 40 kg/m2&#xD;
&#xD;
        10. Subjects with unstable angina&#xD;
&#xD;
        11. Subjects with SBP ≥ 175 mm Hg or DBP ≥ 100 mm Hg&#xD;
&#xD;
        12. Subjects with a decrease in SBP ≥ 20 mm Hg or DBP ≥ 10 mm Hg from sitting to standing&#xD;
        position&#xD;
&#xD;
        13. Subjects who, in the opinion of the investigator, have suspected nonadherence to&#xD;
        antihypertensive treatment&#xD;
&#xD;
        14. Subjects who, in the opinion of the investigator, have any major medical illness or&#xD;
        symptoms&#xD;
&#xD;
        15. Subjects who, in the opinion of the investigator, have any acute or chronic medical or&#xD;
        psychiatric condition&#xD;
&#xD;
        16. Subjects undergoing treatment with any of the following medications:&#xD;
&#xD;
          1. Topical corticoids&#xD;
&#xD;
          2. Sympathomimetic decongestants&#xD;
&#xD;
          3. Theophylline&#xD;
&#xD;
          4. Phosphodiesterase type 5 inhibitors&#xD;
&#xD;
          5. NSAIDs&#xD;
&#xD;
          6. Intramuscular steroids&#xD;
&#xD;
          7. Estrogen&#xD;
&#xD;
          8. Cytochromes&#xD;
&#xD;
          9. Strong CYP3A and CYP3A4 inducers&#xD;
&#xD;
             17. Subjects with known hypersensitivity to MLS-101 or any of the excipients&#xD;
&#xD;
             18. Subjects who are night-shift workers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christina Franco, MPH</last_name>
    <phone>1-919-366-7618</phone>
    <email>christina.franco@novellaclinical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 103</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leesa Koskela</last_name>
      <phone>916-434-8230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 129</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sajad Hamal</last_name>
      <phone>310-803-5657</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 135</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dora Godinez</last_name>
      <phone>714-550-9990</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 131</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas A Smircic</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 105</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio C Gomez</last_name>
      <phone>305-445-5637</phone>
      <phone_ext>217</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 108</name>
      <address>
        <city>Greenacres City</city>
        <state>Florida</state>
        <zip>33467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Collazo</last_name>
      <phone>561-766-2181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 134</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corine van Grootheest</last_name>
      <phone>561-741-2033</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 146</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 137</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Rodriguez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 139</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Ballester</last_name>
      <phone>305-631-6704</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 143</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Alvarez</last_name>
      <phone>1-844-NPRESEARCH</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 122</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenia Leyva</last_name>
      <phone>954-885-5555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 102</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Keskiner</last_name>
      <phone>813-870-1292</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 118</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <zip>31707</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Latonya Rucker</last_name>
      <phone>229-352-8337</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 109</name>
      <address>
        <city>Fayetteville</city>
        <state>Georgia</state>
        <zip>30214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atira Goodwin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 125</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malede Mengistu</last_name>
      <phone>678-822-5581</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 136</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Bellini</last_name>
      <phone>847-483-0690</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 138</name>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Terry</last_name>
      <phone>318-626-5180</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 154</name>
      <address>
        <city>Hammond</city>
        <state>Louisiana</state>
        <zip>70403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandy Gallodoro Ocman</last_name>
      <phone>985-871-4155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 148</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Terry</last_name>
      <phone>318-626-5180</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 114</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Montgomery</last_name>
      <phone>985-649-2700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 116</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzin Cunningham</last_name>
      <phone>573-556-7785</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 121</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Shultz</last_name>
      <phone>314-567-3377</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 123</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeida Gonzalez</last_name>
      <phone>702-570-6107</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 133</name>
      <address>
        <city>Asheboro</city>
        <state>North Carolina</state>
        <zip>27203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Alfonsin</last_name>
      <phone>336-823-2178</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 113</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shazia Ferdous</last_name>
      <phone>980-236-9478</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 130</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arien Stebbins</last_name>
      <phone>910-302-8151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 140</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alaina Cvetic</last_name>
      <phone>336-763-6968</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 104</name>
      <address>
        <city>Morgantown</city>
        <state>North Carolina</state>
        <zip>28655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert D Keene</last_name>
      <phone>828-391-2024</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 150</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Henderson</last_name>
      <phone>919-781-2514</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 115</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Houk</last_name>
      <phone>605-721-5044</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 107</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misti Earwood</last_name>
      <phone>423-698-4584</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 120</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Whitaker</last_name>
      <phone>423-378-7624</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 151</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megann Eiler-Prater</last_name>
      <phone>817-509-0084</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 145</name>
      <address>
        <city>Cypress</city>
        <state>Texas</state>
        <zip>77429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Afsaneh Morteza</last_name>
      <phone>281-213-2723</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 132</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vickie Martinez</last_name>
      <phone>469-297-3074</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 124</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sana Baig</last_name>
      <phone>972-900-3538</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 147</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75149</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Saeed</last_name>
      <phone>972-777-4428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 128</name>
      <address>
        <city>Richland Hills</city>
        <state>Texas</state>
        <zip>76180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hector Ochoa</last_name>
      <phone>817-595-3399</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 112</name>
      <address>
        <city>Forest</city>
        <state>Virginia</state>
        <zip>24551</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Florow</last_name>
      <phone>434-288-1322</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood pressure</keyword>
  <keyword>Uncontrolled hypertension</keyword>
  <keyword>Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Renal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

